Protein members of the AraC family of bacterial transcriptional activators have great promise as targets for the development of novel antibacterial agents. Here, we describe an in vivo high-throughput screen to identify inhibitors of the AraC family activator protein RhaS. The screen used two Escherichia coli reporter fusions: one to identify potential RhaS inhibitors and a second to eliminate nonspecific inhibitors from consideration. One compound with excellent selectivity, OSSL_051168, was chosen for further study. OSSL_051168 inhibited in vivo transcription activation by the RhaS DNA-binding domain to the same extent as the full-length protein, indicating that this domain was the target of its inhibition. Growth curves showed that OSSL_051168 did not affect bacterial cell growth at the concentrations used in this study. In vitro DNA-binding assays with purified protein suggest that OSSL_051168 inhibits DNA binding by RhaS. In addition, we found that it inhibits DNA binding by a second AraC family protein, RhaR, which shares 30% amino acid identity with RhaS. OSSL_051168 did not have a significant impact on DNA binding by the non-AraC family proteins CRP and LacI, suggesting that the inhibition is likely specific for RhaS, RhaR, and possibly additional AraC family activator proteins.
Introduction
The ever-growing problem of bacterial antibiotic resistance requires the identification and development of novel antibacterial agents. Traditionally, the molecular targets for antibacterial agents have been processes that are essential for bacterial growth. However, inhibition of such essential processes exerts substantial selective pressure for the emergence of resistance mechanisms that overcome the inhibition. 1 One alternative strategy involves targeting virulence factors. The nonessential nature of virulence factors may reduce resistance development, but the substantial antigenic diversity they often exhibit can impede their utility as antimicrobial targets. 1 Alternatively, the activator proteins that are required for the expression of bacterial virulence factors share the advantage of being nonessential but tend to be much more conserved than virulence factors. 1 Unlike the dramatic and long-term effects traditional antibiotics can have, targeting the expression of virulence factors has the potential to be considerably less disruptive to the gut microbiota. Thus, inhibitors of activator proteins that are required by bacterial pathogens for the expression of virulence factors have great potential to be developed into novel antibacterial agents.
Protein members of the large AraC family of transcriptional activators generally activate expression of genes involved in carbon metabolism, stress responses, or virulence. 2 Indeed, large numbers of pathogenic bacteria, including many priority antibiotic-resistant pathogens, require AraC family transcription activators for virulence factor expression and thereby to cause disease (see, e.g., Francis et al. 3 and Yang et al. 4 ). Many AraC family activators are required for the expression of multiple virulence factors; thus, blocking the function of the AraC family activator has the potential to substantially ameliorate virulence and disease. In support of this hypothesis, deletion or inhibition of many AraC family activators of virulence factor expression has been found to dramatically reduce infections (see, e.g., Casaz et al., 5 Champion et al., 6 Coburn et al., 7 Darwin and Miller, 8 Frota et al., 9 Hauser et al., 10 and Hava and Camilli
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). Several previously published studies have identified small-molecule inhibitors of specific AraC family virulence factor regulators [12] [13] [14] [15] [16] [17] and, in several cases, demonstrated that they can dramatically reduce infection in animal models. Among these, the hydroxybenzimidazole class of inhibitors [12] [13] [14] 17 has been found to inhibit seven different AraC family activators, suggesting that these inhibitors may target a relatively conserved feature of the family. These studies, together with the above evidence that deletion of AraC family activators can result in very large reductions in virulence, provide strong evidence that AraC family activators can be effective targets for novel antibacterial agents. However, it is likely that the currently available inhibitors will only be effective against a subset of the medically important AraC family activators. This is based on the family's extremely large size and diversity-they are predicted to have arisen early in the evolution of bacteria, 2 and paralogs typically share only 15% to 30% amino acid sequence identity. Thus, screening for inhibitors of additional family members will likely identify new classes of inhibitors that inhibit additional family members.
Our study involves the AraC family activators RhaS and RhaR, which activate expression of the l-rhamnose catabolic operons in Escherichia coli. 18 RhaR activates expression of the operon that encodes RhaS and RhaR, and RhaS activates expression of the operon that encodes the l-rhamnose catabolic enzymes. 18 Despite the fact that RhaS and RhaR appear to have arisen by gene duplication, and both activate transcription in response to the effector l-rhamnose, they share only 30% identity at the amino acid level.
Given that the ultimate success of developing previously identified AraC inhibitors into antibacterial agents cannot be predicted, and the fact that inhibitors have been identified only for a small fraction of the medically important family members, the goal of our study was to identify novel small-molecule inhibitors of AraC family activators. We used an in vivo high-throughput screen to identify inhibitors of RhaS with the rationale that, similar to the hydroxybenzimidazole class of inhibitors, some might inhibit multiple AraC family activators. The in vivo screen circumvented the solubility problems that plague most AraC family activators and had the further advantage that only compounds that were able to successfully enter Gramnegative bacterial cells would be identified. A secondary screen differentiated the desired RhaS inhibitors from nonspecific inhibitors. The most potent of the inhibitors identified, OSSL_051168, was found to inhibit DNA binding by purified RhaS and RhaR proteins but not by the unrelated CRP (cyclic AMP receptor protein) or LacI proteins.
Materials and Methods

Bacteria, Growth Media, and Growth Conditions
All bacteria were strains of E. coli K-12, except strains for protein overexpression, which were strains of E. coli B (Suppl . Table S1 ). Cultures for the primary high-throughput screen were grown in tryptone broth plus ampicillin (TB; 0.8% Bacto tryptone, 0.5% NaCl, pH 7.0; all % recipes are w/v except glycerol and DMSO, which are v/v). Cultures for subsequent in vivo assays were grown in 3-(N-morpholino)propanesulfonic acid (MOPS)-buffered minimal medium as previously described. 18 Cultures for phage P1vir infection were grown in tryptone-yeast extract broth (TY; 0.8% Bacto tryptone, 0.5% Difco yeast extract, 0.5% NaCl, pH 7.0) supplemented with 5 mM CaCl 2 . Difco Nutrient Agar was used routinely to grow cells on solid medium (Becton Dickinson, Franklin Lakes, NJ). Difco MacConkey Agar Base supplemented with 1% sorbitol or maltose was used to screen for sorbitol-and maltose-deficient phenotypes (Becton Dickinson, Franklin Lakes, NJ). Ampicillin (200 µg/mL), tetracycline (20 µg/mL), chloramphenicol (30 µg/mL), gentamycin (20 µg/ mL), l-rhamnose (0.2%), glucose (0.2%), and isopropyl-β-dthiogalactopyranoside (IPTG; 0.1 mM unless otherwise noted) were added as indicated. All cultures were grown at 37 °C with aeration, unless otherwise noted.
High-Throughput Screening Compound Library
High-throughput screening (HTS) was performed using the compound library at the University of Kansas HighThroughput Screening Laboratory, which consisted of approximately 100 000 compounds. Compounds were purchased from ChemBridge Corp. (San Diego, CA), Chemdiv (San Diego, CA), Prestwick Chemicals (Illkirch, France), and MicroSource Discovery Systems (Gaylordsville, CT). Compounds were selected based on structural diversity and drug-like properties.
Primary High-Throughput Screen
An overnight culture of E. coli strain SME3006 (Suppl .  Table S1 ) grown in TB with ampicillin was diluted 1:100 into fresh TB with ampicillin that had been prewarmed to 37 °C. Cells were grown to an OD 600 of 0.1, and growth was stopped on ice for approximately 30 min. Using a Multidrop 384 (Thermo Scientific, Hudson, NH), 35 µL of this cell culture was added to each well of a 384-well plate (Nunc, Rochester, NY). In addition to cells, each well in column 1 of the plate contained 20 µL 2.5% DMSO and 10 µL water (uninduced control), each well in column 2 contained 20 µL 2.5% DMSO and 10 µL 2% l-rhamnose (induced control), and each well in columns 3 to 24 contained 20 µL of a library compound at 25 µg/mL in 2.5% DMSO and 10 µL 2% l-rhamnose. Plates were incubated statically for 3 h at room temperature to allow rhaB-lacZ induction, followed by addition of 25 20 for each individual 384-well plate screened.
HTS Strain Construction
The tester strain for the primary high-throughput screen was SME3006. This strain carried the RhaS-activated Φ(rhaB-lacZ)Δ84 fusion 18 in a single copy on the chromosome. The rhaBAD promoter in this fusion includes the full binding site for the RhaS protein but not the upstream binding site for CRP. This ensures that RhaS is the sole activator of this fusion and that inhibition of CRP protein activity would not decrease LacZ expression. This strain also carries ΔrhaS and recA::cat on the chromosome and RhaS expressed from plasmid pHG165rhaS, 18 which modestly increases rhaB-lacZ expression levels compared with chromosomal rhaS expression.
The control strain for the secondary high-throughput screen and subsequent experiments was SME3359 (Suppl . Table  S1 ), which carries the LacI-repressed fusion and LacIexpressing pHG165lacI. The fusion consists of lacZ under the control of an artificial promoter (Phts) with an induced expression level similar to that of the induced rhaBAD operon. Phts is regulated by LacI and induced with IPTG. The Phts core promoter elements include a near-consensus -35 sequence (5′-TTGACT-3′) and a -10 sequence (5′-TACTAT-3′) followed by a lacO 1 operator sequence that overlaps the transcription start site with the same spacing as lacO 1 at lacZYA. To construct the upstream half of Phts, oligo 2829 (5′-CGAgaattc ATTTTAGGCACCCCAGGCTTGACT-3′) was annealed to oligo 2788 (5′-CTAGAActcttcGTAGAGCCGGAAGCATA AAGAGTCAAGCCTGGGGTGCCTAAAAT-3′), and the primers were extended using the Expand High Fidelity PCR System Table S1 ). The sequence of both DNA strands of the cloned region was confirmed (Northwestern University Genomics Core, Chicago, IL). PhtslacZ was recombined onto λRS45 and integrated as a singlecopy lysogen 21 into the chromosome of strain SME1085. Likely single-copy lysogens were identified by β-galactosidase assay 18 and confirmed by PCR. 22 The resulting strain was transformed with LacI-expressing pHG165lacI.
Secondary High-Throughput Screen
We rescreened the top ~5% most inhibitory compounds from the primary screen. The secondary screen was performed essentially as the primary screen, except for the following changes: Cells were grown in MOPS-buffered minimal medium with ampicillin rather than TB with ampicillin. Compounds were tested against both SME3006 and SME3359. For plates containing SME3359, 6.5 mM IPTG was used as the inducer rather than 2% l-rhamnose, and the first and second columns were uninduced and induced controls, analogous to above.
Strain Construction for In Vivo DoseResponse Studies
For dose-response studies, a rhaB-lacZ reporter strain was designed that allowed IPTG induction of RhaS or RhaS(163-278) expression from pHG165 (and thus rhaBlacZ expression). The strain was constructed by introducing malP::lacI q from strain SG22166 into SME3000 via phage P1vir-mediated generalized transduction, by the previous method. 23 The resulting strain, SME3000 malP::lacI q zhc-511::Tn10, was transduced with recA::cat from SME1048 by selecting for chloramphenicol resistance, to make strain SME3632.
In Vivo Dose-Response Experiments
The top hit identified in the screen was 1-ethyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline. The closely related compound, OSSL_051168, 1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline, was obtained from eMolecules (Solana Beach, CA; cat. 3761-0013) or Princeton BioMolecular Research (Princeton, NJ; cat. OSSL_051168), with the Princeton name used here. OSSL_051168 was dissolved in 100% DMSO, and then the solution was further diluted in 100% DMSO in a 2-fold series for a total of seven concentrations. Dose-response assays were performed in 96-well plates with one column each of uninduced and induced controls for each strain and one column with a concentration curve of OSSL_051168 for each strain. Uninduced wells contained 20 µL water and 40 µL 10% DMSO; induced wells contained 20 µL induction solution (2% l-rhamnose and 6.5 mM IPTG) and 40 µL 10% DMSO; concentration curve wells contained 20 µL induction solution, 36 µL water, and 4 µL diluted OSSL_051168. The appropriate cell culture (70 µL, grown to OD 600 = 0.1 in MOPS-buffered minimal medium with ampicillin) was added to each well and induced for 3 h at 37 °C. Lysis/ ONPG buffer (50 µL, as in the primary screen) was added to each well and the plate was immediately placed into a PowerWave XS plate reader (BioTek Instruments, Winooski, VT), set to read the OD 420 of each well every 15 min for 4 h. A single time point within the linear range of β-galactosidase activity was chosen for analysis for each strain. Due to differences in kinetics of lacZ reporter expression, the rhaB-lacZ strains were analyzed at 4 h and the hts-lacZ strain was analyzed at 1 h. Percent activity was calculated for each condition as described above, using the single time point with appropriate OD 420 levels for each strain. Error bars represent the standard error of the mean. IC 50 and maximal inhibition values were calculated using the XLfit add-in for Microsoft Excel (ID Business Solutions, Guildford, UK), and graphs were drawn using Prism (GraphPad Software, La Jolla, CA).
Growth Curves
Strains SME3634 and SME3359 were grown overnight (~16 h) at 37 °C in MOPS-buffered minimal medium. 18 Overnight grown cultures were diluted into the same medium plus l-rhamnose to an OD 600 of 0.1, and IPTG was added. Then, 1-mL aliquots of the cultures were added to wells of a 24-well plate, with the addition of either 44 µM OSSL_051168 (dissolved in 100% DMSO) or an equal volume of 100% DMSO. Growth was monitored at 20-min intervals for approximately 8 h at 37 °C with continuous shaking in a PowerWave XS plate reader (BioTek Instruments). Error bars represent the standard error of the mean.
Protein Purification
All proteins for this study were expressed in E. coli. Untagged CRP was purified by Ni 2+ -affinity chromatography as described. 24 LacI protein was purified by ammonium sulfate precipitation and phosphocellulose column chromatography as described. 25 RhaS-GB1 201b and GB1 bRhaR were purified by Ni 2+ -affinity chromatography. Briefly, plasmids derived from pET21 and expressing RhaS-GB1 201b and GB1 b -RhaR were transformed into competent cells of strains Acella (MoBiTec, Göttingen, Germany) or ArcticExpress(DE3) (Agilent Technologies, Santa Clara, CA), respectively. The cells were grown in 1 L of TY plus ampicillin and l-rhamnose. Gentamycin was also added for GB1 b -RhaR. The cells were grown to an OD 600 of 0.5, transferred to a 15 °C shaker with 0.1 mM IPTG added, and then incubated overnight. Cells were harvested by centrifugation and then resuspended in 30 mL of cold binding buffer (20 mM Tris, 500 mM NaCl, 5 mM imidazole, pH 7.9) plus l-rhamnose. Cells were lysed by three cycles of freeze-thaw (with addition of lysozyme [0.4 mg/mL], tris(2-carboxyethyl)phosphine [TCEP, 1 mM], and phenylmethylsulfonyl fluoride [PMSF, 1 mM], at −80 °C), followed by sonication, and then centrifuged to remove cell debris. The supernatant was applied using an AKTAexplorer FPLC (GE Healthcare, Piscataway, NJ) to a 5-mL HiTrap Chelating HP column (GE Healthcare) that had been charged with 50 mM NiSO 
In Vitro DNA-Binding Assays
Electrophoretic mobility shift assays were performed as described, 26 TGTTGTGTGGAATTGTGAGCGG ATAA CAATTTCACACAGG-3′) and oligo O1-Rev (5′-CCTGTGTGAAATTGTTATCCGCTCACAATTCC ACACAAC A-3′). IRD700-and DY682-labeled oligos were from Eurofins MWG Operon. For each oligo pair, 100 µmol of each oligo was combined and the reaction was diluted in STE buffer (50 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0) to 20 µL, heated to 94 °C for 2 min, and cooled to room temperature. The double-stranded DNA probes were further diluted in STE and 0.3 to 1 µL added to EMSA reactions. To ensure that protein was limiting in the reactions, protein concentrations were adjusted so that less than 100% of the total DNA was bound in the absence of inhibitor (55%-85% bound DNA among the replicates for all of the proteins assayed). EMSA gels were imaged using an Odyssey infrared imager (LI-COR, Lincoln, NE) and quantified using the Odyssey software, version 3.0.30. The quantity of DNA bound with 10 µM inhibitor was approximately equal to the bound DNA in the absence of inhibitor and was set to 100% for RhaS-GB1 201b , GB1 b -RhaR, and LacI. For CRP, the quantity of DNA bound in the absence of inhibitor was set to 100%. Error bars represent the standard error of the mean. Inhibition values were calculated and graphs were drawn as for in vivo dose-response experiments.
Results
High-Throughput Screen to Identify Inhibitors of AraC Family Activators
Our goal was to use HTS to identify novel inhibitors that could block the function of AraC family activator proteins. Ultimately, such inhibitors have the potential to be developed into antibacterial agents that block virulence factor expression in human pathogens. Although it does not regulate virulence factor expression in any human pathogens, we chose the RhaS protein as our initial target since the molecular mechanisms used by RhaS to activate transcription are well characterized (see, e.g., Kolin et al. 18 and Wickstrum et al. 26 ).
The first step of our in vivo high-throughput screen for RhaS inhibitors was to screen for compounds that decreased expression of a RhaS-activated rhaB-lacZ reporter fusion in whole cells (Fig. 1A, top) . Screening in whole cells (rather than with purified protein) was advantageous for two reasons. First, RhaS is very insoluble, and purified, active RhaS protein was not available at the time of this screen. Second, whole-cell screens are expected to identify only compounds that can enter and remain active in the bacterial cell. The disadvantage of our whole-cell assay was that many compounds were expected to affect RhaS-activated LacZ reporter activity without directly affecting activation by RhaS. To screen out the vast majority of such indirect effects, each compound that reduced the RhaS-activated LacZ reporter activity in the primary screen was retested, both on the primary screening strain and on a secondary screening strain. The secondary screening strain was an isogenic control strain carrying a lacZ reporter fusion (htslacZ), with a synthetic promoter that was repressed by LacI and did not require RhaS for activation (Fig. 1A, bottom) . Nonspecific inhibitors that blocked β-galactosidase enzyme activity or cell growth, for example, were expected to decrease lacZ expression from both rhaB-lacZ and hts-lacZ. In contrast, the compounds of interest that specifically inhibited RhaS were expected to decrease lacZ expression from rhaB-lacZ (primary screen) but not from hts-lacZ (secondary screen).
We screened a library of ~100 000 small-molecule compounds for those that decreased rhaB-lacZ expression in the primary screening strain using a high-throughput β-galactosidase assay (modified from Alksne et al. 19 ). All but 3 of the 295 plates (384-well) assayed had Z factors of 0.5 or above, and the remaining 3 plates had Z factors above 0.4. (The Z′ scores in the 0.4 range could be traced to one or two positive or negative control wells on each plate with somewhat aberrant signals.) The average of the Z factors for all plates was 0.7, indicating that this was an excellent assay. 20 A major contribution to the performance of the assay was that the positive and negative controls had coefficients of variation of only 2% to 3% over the entire assay.
The inducer for RhaS activation of rhaBAD transcription, l-rhamnose, was added to the assay wells at the same time as the compounds. In this way, rhaB-lacZ expression was uninduced until exposure to the compounds, and it was not necessary for preformed β-galactosidase to decay before inhibition could be detected. We further studied compounds that resulted in rhaB-lacZ expression levels that were at least three standard deviations below the mean of all compounds in the study. This allowed us to focus further efforts on a convenient number of compounds likely to show significant inhibition. These compounds decreased rhaB-lacZ expression levels to between 0% and 75% of the fully induced, noninhibited control expression levels (data not shown).
The ~300 most inhibitory compounds from the primary screen (~0.3% hit rate) were reassayed with both the RhaSactivated rhaB-lacZ fusion and the LacI-repressed control hts-lacZ fusion (data not shown). IPTG, the inducer of the LacI-repressed hts-lacZ fusion, was added to the assay wells at the same time as the compounds. Similar to addition of the inducer l-rhamnose to the primary screen, this resulted in LacZ expression that was uninduced until exposure to compounds. We ranked each compound by the difference in lacZ expression levels between the RhaS-activated and the LacI-repressed fusions. Expression levels were normalized to the average of the uninduced controls (set to 0%) and the average of the induced controls (set to 100%). The data were plotted as a scatter plot of the RhaS-activated (x-axis) versus LacI-repressed (y-axis) expression levels. Compounds that inhibited expression from the RhaSactivated fusion to a greater extent than the LacI-repressed fusion (upper left quadrant of plot) were likely specific inhibitors of RhaS activity and were of further interest. We selected the 16 compounds that best fit these criteria for further study as potential specific RhaS inhibitors. These compounds exhibited considerable structural diversity.
Dose-Dependent Inhibition of RhaS
We tested the effects of various concentrations of the 16 potential RhaS inhibitors on activation of the RhaS-activated fusion compared with the LacI-repressed fusion to identify those with dose-dependent inhibition (data not shown). The set of hits displayed considerable structural diversity, including various heterocyclic ring systems having a range of drug-like properties. One of the compounds showed particularly robust, dosedependent inhibition of the RhaS-activated fusion and substantially less inhibition of the LacI-repressed fusion. In addition, its structure was viewed as amenable for potential medicinal chemistry optimization. We further describe studies of OSSL_051168, which is nearly identical in structure to the compound identified in the screen, was readily available commercially, and inhibited to the same extent as the screen compound (data not shown) (Fig. 1B,C) . We found that OSSL_051168 inhibited expression of the RhaS-activated rhaB-lacZ fusion to a much greater extent than the LacIrepressed hts-lacZ fusion (Fig. 2, circle and square markers) . OSSL_051168 was able to fully inhibit expression of the RhaS-activated fusion and had an IC 50 value of approximately 30 µM. Although there was a small amount of nonspecific inhibition, the majority of the OSSL_051168 inhibition appears to be specific for RhaS. OSSL_051168 is not structurally related to any of the inhibitors of AraC family activators that have been previously identified.
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OSSL_051168 Inhibited the RhaS DNABinding Domain to the Same Extent as Full-Length RhaS
The first step we took toward identifying the mechanism of RhaS inhibition by OSSL_051168 was to determine whether the RhaS N-terminal domain was required for the inhibitory effect. Proteins are defined as AraC family members if they contain a conserved DNA-binding domain that includes two helix-turn-helix motifs, as defined by Prosite entry PS01124 (prosite.expasy.org/PS01124). 2 The RhaS C-terminal DNA-binding domain alone (residues 163-278, RhaS(163-278), previously published as RhaS-CTD) is capable of activating transcription of the rhaB-lacZ fusion used in these studies, albeit to approximately a 3-fold lower level than full-length RhaS. 27 We therefore compared the effect of OSSL_051168 on activation of the RhaS-activated rhaB-lacZ fusion by full-length RhaS and RhaS(163-278) (Fig. 2) . We found that OSSL_051168 inhibited RhaS(163-278) to at least the same extent as full-length RhaS. OSSL_051168 was again able to fully inhibit expression, this time with an IC 50 value of approximately 10 µM. This result indicates that the RhaS N-terminal domain, which is required for dimerization and l-rhamnose binding, is not required for OSSL_051168 inhibition of RhaS. We therefore conclude that OSSL_051168 specifically inhibits a function of the RhaS DNA-binding domain-likely DNA binding or contacts with the RNA polymerase σ subunit.
OSSL_051168 Does Not Inhibit Cell Growth
All of our assays to this point were performed in whole cells, and thus it was important to test whether OSSL_051168 had any significant effects on the growth of the bacterial cells. We assayed the growth of the strains carrying the RhaS-activated and the LacI-repressed fusions, grown in the same minimal medium used for the in vivo dose-response assays. We found that there was no impact of the inhibitor on the growth of the cells for either strain (Suppl . Fig. S1 ). There was a very slight divergence of the plus and minus inhibitor curves at the end of the growth period, but this was not due to inhibitor toxicity since the cells grown without inhibitor had the slower growth. This result supports the hypothesis that the inhibition we observed in the in vivo assays was likely due to specific inhibition of RhaS activation.
OSSL_051168 Inhibits In Vitro DNA Binding by RhaS and RhaR
To perform in vitro DNA binding assays with RhaS, we needed purified protein that was soluble and active. With the exception of low levels of activity from denatured and subsequently refolded protein, 28 we have not previously been able to observe in vitro DNA binding by full-length RhaS, apparently due to its extremely low solubility. Two modifications were required to obtain soluble and active RhaS for these studies. First, we used a RhaS variant, RhaS L201R, 18 which binds DNA more strongly than wild-type RhaS. The second modification was to fuse a GB1 basic solubility-enhancement tag 29 to the C-terminus of full-length RhaS L201R, yielding RhaS L201R-GB1 basic (referred to as RhaS-GB1 201b for brevity). The "basic" variant of GB1 was necessary to prevent tight binding between RhaS and GB1 that blocked DNA binding (J. M. Skredenske, J. Deng, and S. M. Egan, unpublished data). RhaS-GB1 201b is soluble and binds DNA in vitro, with increased DNA binding in the presence of l-rhamnose (J. Deng and S. M. Egan, unpublished data), as expected for functional RhaS based on previous studies. 28 We used the electrophoretic mobility shift assay (EMSA) to investigate whether OSSL_051168 inhibited in vitro DNA binding by . We incubated RhaS-GB1 201b with dsDNA containing the RhaS binding site sequence from the rhaBAD promoter region (this includes binding sites for both monomers of the RhaS-GB1 201b dimer) in the absence or presence of various concentrations of OSSL_051168. We found that OSSL_051168 was able to fully inhibit DNA binding by RhaS-GB1 201b in a dose-dependent manner (Fig. 3A) . We calculated an IC 50 of approximately 70 µM, which is in reasonable agreement with the 30-µM IC 50 calculated from the in vivo assays of RhaS inhibition, especially considering the many experimental differences. From this result, we conclude that the inhibition of RhaS activity observed in the in vivo assays was likely due to OSSL_051168 blocking the ability of RhaS to bind to DNA.
We also tested the ability of OSSL_051168 to inhibit DNA binding by the RhaR protein. As mentioned above, although RhaS and RhaR both activate transcription in response to the effector l-rhamnose, they are only 30% identical to each other. The identity in their DNA-binding domains is approximately the same, at 34% amino acid identity. E. coli AraC family activators have pairwise amino acid identities that range from single digits to 56%, and thus RhaS and RhaR share an intermediate level of identity.
We purified RhaR as a fusion protein with GB1 basic , GB1 b -RhaR, which resulted in soluble protein that was active for DNA binding-showing the expected increase in DNA binding in the presence of l-rhamnose (J. Deng and S. M. Egan, unpublished data). We found that OSSL_051168 inhibited DNA binding by purified GB1 b -RhaR protein to approximately the same extent as RhaS-GB1 201b protein (Fig. 3B) . OSSL_051168 was able to fully inhibit 
OSSL_051168 Does Not Inhibit DNA Binding by Non-AraC Family Proteins
Our results indicated that OSSL_051168 inhibits DNA binding by both the RhaS and RhaR proteins. We used two unrelated proteins, the cyclic AMP receptor protein (CRP) and the Lac repressor protein (LacI), to test whether OSSL_051168 was specific for inhibition of RhaS and RhaR (and perhaps other AraC family proteins) or was broadly inhibitory toward DNA binding proteins. CRP and LacI each share only 10% to 12% sequence identity with RhaS and RhaR. Neither CRP nor LacI contains the two helix-turn-helix motifs (per monomer) characteristic of AraC family proteins.
2 Broad inhibition of DNA binding by OSSL_051168 would be expected to have a major impact on cell growth; therefore, the finding that OSSL_051168 had minimal impact on growth of the strains used for our in vivo studies (Suppl. Fig. S1 ) was the first evidence that broad inhibition was unlikely.
We first tested the effect of OSSL_051168 on DNA binding by CRP. EMSA reactions were performed with varying concentrations of purified CRP protein. The OSSL_051168 concentration (1.3 mM) was two times higher than the concentration required in the in vitro assays to nearly eliminate RhaS binding to DNA. We found that even at this very high concentration of OSSL_051168, approximately 94% of the CRP DNA binding was retained (Fig. 4A) . Thus, OSSL_ 051168 resulted in only a very slight inhibitory effect on DNA binding by CRP.
As a second test of whether OSSL_051168 inhibition is specific for AraC family activators, we tested the lac repressor protein, LacI (Fig. 4B) . EMSA assays were again performed; in this case, various dilutions of OSSL_051168 (starting at 650 µM) were added to reactions with LacI protein at a concentration just sufficient to shift nearly the entire DNA band. The highest concentrations of OSSL_051168 had only a slight effect on LacI DNA binding, with approximately 70% of DNA binding retained. Note that this in vitro test of LacI binding to DNA was not redundant with the in vivo hts-lacZ reporter assay since LacI was in its induced state in the reporter assay and therefore not bound to DNA.
Taken together, the CRP and LacI results indicate that OSSL_051168 does not simply inhibit the activity of all DNA-binding proteins, and furthermore, not all helixturn-helix-containing proteins are inhibited. It has yet to be determined whether OSSL_051168 is specific for only RhaS and RhaR. However, the above finding that OSSL_051168 inhibits RhaR, a protein with only 30% identity with RhaS, suggests the possibility that OSSL_051168 might inhibit DNA binding by additional AraC family proteins, perhaps including activators of virulence factor expression in bacterial pathogens.
Discussion
Screening Identified Inhibitors of AraC Family Activators
Members of the AraC family of transcriptional activators have excellent potential as targets for novel antibacterial agents based on the fact that they are required for the expression of virulence factors in many bacterial pathogens (see, e.g., Casaz et al., 5 Champion et al., 6 Coburn et al., 7 Darwin and Miller, 8 Frota et al., 9 Hauser et al., 10 and Hava and Camilli 11 ). These include many bacteria that pose serious human health threats due to their resistance to currently available antibiotics. Thus, there is an urgent need for novel antibacterial agents. The goal of this study was to screen for and begin to characterize small-molecule inhibitors of AraC family transcriptional activators. Such inhibitors will be useful in the study of bacterial pathogenesis and have the potential to be developed into novel antibacterial agents. Although several previous inhibitors of AraC family activators have been identified, [12] [13] [14] [15] [16] [17] the diversity of proteins in the family indicates the likelihood that the current inhibitors will only be effective against a subset of family members.
We developed and validated a novel high-throughput assay to screen for small-molecule inhibitors of the E. coli AraC family activator protein RhaS. The in vivo assay achieved specificity for RhaS inhibitors through comparison of expression levels from two reporter constructs: one that was transcriptionally activated by RhaS and a second that was transcriptionally repressed by the non-AraC family repressor LacI. The LacI-repressed reporter enabled us to identify and eliminate nonspecific inhibitors from consideration. Of the compounds identified in our screen, we further investigated one compound, OSSL_051168, which was an especially effective inhibitor of RhaS. OSSL_051168 is not structurally related to any of the previously identified small-molecule inhibitors of AraC family activators and thus is a novel inhibitor.
Specificity and Potency of OSSL_051168
Given that OSSL_051168 was identified through a whole-cell high-throughput screen and has not undergone chemical optimization, its potency is very reasonable. The following results indicate that the majority of the OSSL_051168 inhibition that we observed in whole-cell assays was specific for AraC family proteins. First, we found very little inhibition of expression from the control fusion, hts-lacZ, indicating that there was not significant inhibition of β-galactosidase enzyme activity or of any processes that affected transcription or growth rate. The absence of an impact of OSSL_051168 on E. coli growth rate was more directly confirmed by comparing cell growth rates in the absence and presence of OSSL_051168. Finally, we determined that OSSL_051168 had only very little effect on DNA binding by two proteins unrelated to the AraC family and unrelated to each other, CRP and LacI. This result suggests that OSSL_051168 does not inhibit by a nonspecific mechanism such as binding to DNA to block protein binding. Since both CRP and LacI use helix-turnhelix motifs to contact DNA, this finding also suggests that OSSL_051168 does not generally block DNA binding by helix-turn-helix-containing proteins. Therefore, it appears that inhibition by OSSL_051168 involves binding to some feature that is unique to RhaS, RhaR, and possibly additional AraC family activator proteins.
Mechanism of Action: OSSL_051168 Inhibits the Conserved AraC Family DNA-Binding Domain
In addition to their conserved DNA-binding domains, the majority of AraC family proteins contain a second, nonconserved domain that regulates the activity of the DNAbinding domain and in some cases imparts dimerization. 2 The mechanism of action has been published for several previously identified AraC family small-molecule inhibitors. The first was virstatin, which inhibits dimerization by binding to the ToxT effector-binding pocket in the nonconserved domain and mimicking negative regulators of ToxT activity, such as palmitoleic acid. 30 The finding that virstatin targets the nonconserved AraC family protein domain suggests that it is likely to inhibit a relatively narrow set of AraC family activators. (There are advantages and disadvantages to both narrow and broad-spectrum antibacterial agents.) In contrast, the hydroxybenzimidazole class of inhibitors targets a number of different AraC family proteins. [12] [13] [14] 17 Several compounds in this class of inhibitors have been shown to block DNA binding. [12] [13] [14] 17 Overall, the data from these publications support a model in which the hydroxybenzimidazole class of inhibitors targets the AraC family DNA-binding domain.
Given the uncertainties inherent in the development of compounds into drugs and the enormous diversity of AraC family proteins, we screened for additional inhibitors of AraC family activators, specifically the E. coli RhaS protein. We identified OSSL_051168, which is a novel inhibitor of AraC family activators that is not structurally related to the previously identified inhibitors. Our findings indicate that OSSL_051168 inhibits the activity of the more conserved of the two RhaS domains, the DNA-binding domain. Thus, OSSL_051168 might inhibit the activity of additional AraC family proteins, and indeed, we found that OSSL_051168 also inhibited DNA binding by RhaR. Taken together, our results lead to the hypothesis that the OSSL_051168 mechanism of action involves binding to the DNA-binding domain of AraC family proteins and blocking their ability to bind to DNA (Suppl . Fig. S2 ).
